“Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib Vs Placebo in Patients With Stage III BRAFV600E K-Mutant Melanoma”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S43, https://doi.org/10.25251/skin.2.supp.43.